IceCure Medical (NASDAQ:ICCM) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) issued its quarterly earnings results on Thursday. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million.

IceCure Medical Trading Down 2.3 %

Shares of NASDAQ:ICCM traded down $0.03 during midday trading on Friday, hitting $1.08. 48,127 shares of the stock were exchanged, compared to its average volume of 519,405. The business’s 50-day moving average price is $1.32 and its 200 day moving average price is $0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The stock has a market capitalization of $59.94 million, a price-to-earnings ratio of -3.72 and a beta of 0.37.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a research note on Friday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.